Total revenue from operations slipped 7.89 per cent year-on-year to Rs 3,951.96 crore. ...More

Total revenue from operations slipped 7.89 per cent year-on-year to Rs 3,951.96 crore. ...Less

Revenues from overseas business increased to Rs 1,917 crore against Rs 1,631.8 crore, Y-o-Y. Domestic biz ...More

Revenues from overseas business increased to Rs 1,917 crore against Rs 1,631.8 crore, Y-o-Y. Domestic biz revenues increased to Rs 750.8 crore against Rs 669 crore Y-o-Y. ...Less

According to analysts, the company’s US business is seen growing around 30 per cent while domestic busine ...More

According to analysts, the company’s US business is seen growing around 30 per cent while domestic business may see a growth of 10 – 12 per cent. ...Less

Total revenue from operations stood at Rs 4,359.65 crore for the second quarter. ...More

Total revenue from operations stood at Rs 4,359.65 crore for the second quarter. ...Less

Seven NSE largecap companies, including HDFC Bank and Bajaj Finance, posted their highest quarterly profi ...More

Seven NSE largecap companies, including HDFC Bank and Bajaj Finance, posted their highest quarterly profits in 10 quarters, reflecting strong growth and robust financial performance. ...Less

Among the NSE large-cap segment, 9 stocks, including BPCL, Lupin and Shree Cement, recorded over 50% EBIT ...More

Among the NSE large-cap segment, 9 stocks, including BPCL, Lupin and Shree Cement, recorded over 50% EBITDA growth in the September '25 quarter compared to the same period last year. ...Less

Lupin shares saw an uptick after Jefferies raised its target price and reiterated a “Buy” rating post-str ...More

Lupin shares saw an uptick after Jefferies raised its target price and reiterated a “Buy” rating post-strong Q2 results. The US business hit a multi-year high with $315 million in sales, supported by new launches and robust margins, prompting upward revisions to FY26–FY27 earnings and growth outlook. ...Less

Lupin shares rose on Friday after the pharma major reported a robust 73% YoY surge in Q2 FY26 PAT to Rs 1 ...More

Lupin shares rose on Friday after the pharma major reported a robust 73% YoY surge in Q2 FY26 PAT to Rs 1,485 crore, driven by strong sales growth, margin expansion, and operational efficiency. Revenue jumped 24% YoY to Rs 6,831 crore, while EBITDA soared 76%. ...Less

The Big Bull has mildly lowered his holding in Titan, but maintained it in the remaining two over the pas ...More

The Big Bull has mildly lowered his holding in Titan, but maintained it in the remaining two over the past couple of quarters. ...Less